Clear and accurate results to help you stay a step ahead of your cancer
The next-generation Oncodetect® test spotlights very faint signals of cancer DNA in your blood, now tracking 5,000 variants with over 99% specificity. The test can detect cancer recurrence more than 2 years earlier than traditional surveillance methods, like imaging.
What does the Oncodetect test do?
It detects fragments of DNA from your tumor to help you understand your risk of recurrence and monitor response to therapy or surgery.
Is this test right for you?
The Oncodetect Molecular Residual Disease (MRD) test is for patients who have been diagnosed with solid cancers.
What kind of sample does the test use?
Both your tumor and your blood are tested. The initial test analyzes tumor tissue from your surgery or biopsy, while monitoring tests check for signs of cancer in your blood over time.
Is my cancer gone? Is it responding to treatment? Could it come back?
You are one-of-a-kind — and so is your tumor. That’s why the Oncodetect MRD test looks for circulating tumor DNA (ctDNA) shed by your specific tumor. The results can help you and your health care provider make more informed decisions about your treatment path.
Measure ctDNA levels to understand if signs of cancer remain after surgery3,4
Monitor your response to surgery or adjuvant therapy, such as chemotherapy3,4
Understand if you are at a higher risk of your cancer coming back3,4
Is this test right for me?
If you’ve been diagnosed with a solid tumor,
Will insurance cover my test?
We believe everyone should be able to make confident, informed decisions about their cancer treatment. Our team is here to help you understand and navigate the insurance and billing process, and can assist with prior authorizations, billing insurance, appealing denied claims, and providing flexible payment options when necessary.
Medicare covers multiple molecular residual disease (MRD) tests across solid tumor types. More than 91% of patients who received the first generation Oncodetect test paid nothing at all, while 95% of those who had a financial responsibility paid less than $100.
An estimated 3 million patients in the United States alone could benefit from MRD testing.†
Insights to help you plan your next steps with confidence
The Oncodetect MRD test is highly sensitive, so it’s able to detect even tiny fragments of ctDNA shed into the bloodstream from your tumor.
Earlier answers
Molecular residual disease (MRD) testing can detect evidence of cancer up to two years earlier than standard surveillance methods like imaging, giving you more time to plan your treatment path.
Personalized results
By tracking up to 5,000 gene variants specific to your tumor, the next-generation Oncodetect test grants more opportunities to detect ctDNA in the blood than our first-generation test.
How does the test work?
First, we analyze your tumor tissue to create a personalized profile around your cancer’s unique DNA. Then we look for fragments of that DNA in your blood to find out if your cancer is still present or if it is more likely to recur.